10. Hi-Tech Pharmacal

By Nesa Nourmohammadi

2011 generic drug sales: $192 million
Growth rate 2011: 22%
Growth rate 2010: 22%

In 2007 and 2008, Amityville, NY-based Hi-Tech Pharmacal was on a downward spiral. Its sales were stagnant. It was losing money. Its sales were stagnant. But after regaining ground in 2009, Hi-Tech skyrocketed to new heights in 2010 and 2011.

One generic wins a large share of the credit for Hi-Tech's growth in recent years. Its Flonase knockoff, Fluticasone, is Hi-Tech's headlining star, generating $99.4 million in sales for the 2012 fiscal year that ended in April. That's up from $73.8 million for fiscal 2011. Fluticasone is by far the company's biggest-selling generic, and represents more than 40% of net sales. 

Other noteworthy drugs include its second best-selling franchise: eye drops based on Merck's Cosopt and Trusopt products, used to treat glaucoma. Together, these two copycat products accounted for $27 million of Hi-Tech's sales. Its third best-seller is a knockoff form of Bactrim, a Roche ($RHHBY) antibiotic. And then there is its copycat Levaquin, which launched last June as the Johnson & Johnson antibiotic fell off patent. All that helped Fortune magazine rank Hi-Tech Pharmacal third in its list of the 100 fastest-growing companies of 2011.

10. Hi-Tech Pharmacal

Suggested Articles

The FDA has slapped a U.S. drug repackager, saying in a warning letter that its storage processes and equipment cleaning are not up to expectations.

In an effort to stop an Ebola outbreak that has claimed 2,200 lives at the Rwanda border, J&J is shipping 200,000 doses of its vaccine to the country.

By extending the tender offer for just six days, Roche seems confident it will receive positive reviews from U.S. and U.K. watchdogs in time.